Canada-based TSO3 has entered into commercial agreement with Getinge Infection Control, in a bid to support the launch of STERIZONE VP4 sterilization system.
Under the non-exclusive deal, Getinge will distribute the product in multiple markets in which the company has significant market share, including North America and other selected markets.
TSO3 president and CEO R.M. (Ric) Rumble said: "Getinge has watched the progression of our technology through the US regulatory process and with US clearance now in-hand, both organizations see the opportunity to launch this superior technology in North America and selected additional markets.
Developed by TSO3, the STERIZONE VP4 Sterilizer is a dual sterilant, low temperature sterilization system, which uses vaporized hydrogen peroxide (H2O2) and ozone.
Having received approval for commercialization in the US in December 2014, the dynamic sterilant delivery system automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature.
Claimed to allow cost effective error-free sterilization process, the system’s single cycle can sterilize a large number and wide range of compatible devices.
The system is said to increase throughput and minimize sterilization cost, with its 75lb load capacity and a short cycle time.
Getinge Infection Control North America president and CEO Andrew Ray said: "Our entire organization is anxious to get started assisting our mutual customers understand how this technology improves their process and reduces the cost of sterilization while improving patient outcomes."
TSO3 develops products for sterile processing areas in the hospital environment and offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.